In this episode, I discuss the upcoming discontinuation of compounded GLP-1 medications like semaglutide and tirzepatide, which many relied on due to affordability. I explain the differences between compounded and generic drugs, highlighting safety concerns and dosing risks associated with unregulated compounds. With these medications being removed from the market, I emphasize the importance of maintaining healthy lifestyle habits and exploring alternatives such as brand-name medications, self-pay programs, or other weight-loss treatments like phentermine or Contrave. Lastly, I encourage advocacy for better insurance coverage, reminding listeners that progress takes time and consistency is key to long-term success.
Episode Highlights:
• The upcoming discontinuation of compounded GLP-1 medications
• Differences between compounded, generic, and brand-name medications
• FDA regulations and the loophole that allowed compounded versions during shortages
• Safety risks associated with compounded medications
• Alternative weight-loss options
• The importance of maintaining lifestyle habits
• Advocacy for better insurance coverage and the role of Congress in expanding obesity treatment access
============================
FOLLOW ME 👇
Facebook: https://www.facebook.com/drshellymd
Instagram: https://www.instagram.com/drshellymd/
Twitter: https://twitter.com/drshellymd
LinkedIn: https://www.linkedin.com/in/drshellymd/
Website: https://drshellymd.com/
Podcast: https://drshellymd.com/podcast/
============================